Search results
Results from the WOW.Com Content Network
The dendritic cell-based cancer vaccine is an innovation in therapeutic strategy for cancer patients. Dendritic cells (DCs) are antigen presenting cells for the induction of antigen specific T cell response. [1] DC-based immunotherapy is safe and can promote antitumor immune responses and prolonged survival of cancer patients. [2]
Pain and sensory abnormalities can persist for months or years after treatment completion. Some patients may experience “coasting,” where symptoms intensify after completion of treatment. [3] As such, patients can be cancer-free and still suffer from disabling neuropathy induced by cancer treatment. [3]
It is given by injection into a vein. [2] Side effects may include irritation of the vein in which it is given, high blood sugar, and swelling. [2] [3] Excess use may result in low blood sodium and other electrolyte problems. [2] Intravenous sugar solutions are in the crystalloid family of medications. [4]
This is not considered to be parenteral nutrition as it does not prevent malnutrition when used on its own. Standardized solutions may also differ between developers. Following are some examples of what compositions they may have. The solution for normal patients may be given both centrally and peripherally.
In the cancer disease state, the interaction of PD-L1 on the tumor cells with PD-1 on a T-cell reduces T-cell function signals to prevent the immune system from attacking the tumor cells. [9] Use of an inhibitor that blocks the interaction of PD-L1 with the PD-1 receptor can prevent the cancer from evading the immune system in this way. [9]
Its main purpose is to ensure that self-reactive T and B cells which escaped central tolerance do not cause autoimmune disease. [1] Peripheral tolerance can also serve a purpose in preventing an immune response to harmless food antigens and allergens. [2] Self reactive cells are subject to clonal deletion or clonal diversion.
A SERS-based multiplex protein biomarker detection platform in a microfluidic chip can be used to detect several protein biomarkers to predict the type of disease and critical biomarkers and increase the chance of diagnosis between diseases with similar biomarkers (e.g. pancreatic cancer, ovarian cancer, and pancreatitis).
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare type of myeloid cancer in which malignant pDCs infiltrate the skin, bone marrow, central nervous system, and other tissues. Typically, the disease presents with skin lesions (e.g. nodules, tumors, papules , bruise-like patches, and/or ulcers) that most often occur on the head, face ...